Patrizia Nanni

Patrizia Nanni

Università degli Studi di Bologna

H-index: 55

Europe-Italy

About Patrizia Nanni

Patrizia Nanni, With an exceptional h-index of 55 and a recent h-index of 23 (since 2020), a distinguished researcher at Università degli Studi di Bologna, specializes in the field of Oncologia, Immunologia dei tumori.

His recent articles reflect a diverse array of research interests and contributions to the field:

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), through an innovative virus-like particles (VLP)-based vaccine, enhance the antitumoral activity of a HER-2-VLP …

Virus-like particle (VLP) vaccines for cancer immunotherapy

ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug …

P596: clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with a BCR inhibitor. A campus CLL experience

Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft

IFN-γ and CD38 in Hyperprogressive Cancer Development

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy

Patrizia Nanni Information

University

Position

___

Citations(all)

9326

Citations(since 2020)

1837

Cited By

8326

hIndex(all)

55

hIndex(since 2020)

23

i10Index(all)

138

i10Index(since 2020)

47

Email

University Profile Page

Università degli Studi di Bologna

Google Scholar

View Google Scholar Profile

Patrizia Nanni Skills & Research Interests

Oncologia

Immunologia dei tumori

Top articles of Patrizia Nanni

Title

Journal

Author(s)

Publication Date

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), through an innovative virus-like particles (VLP)-based vaccine, enhance the antitumoral activity of a HER-2-VLP …

European Journal of Cancer

F Ruzzi

L Scalambra

MS Semprini

OM Pittino

C Cappello

...

2024/3/1

Virus-like particle (VLP) vaccines for cancer immunotherapy

Francesca Ruzzi

Maria Sofia Semprini

Laura Scalambra

Arianna Palladini

Stefania Angelicola

...

2023/8/19

ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug …

Translational Lung Cancer Research

Francesca Ruzzi

Stefania Angelicola

Lorena Landuzzi

Elena Nironi

Maria Sofia Semprini

...

2022/11

P596: clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with a BCR inhibitor. A campus CLL experience

HemaSphere

Riccardo Bomben

Francesca Maria Rossi

Filippo Vit

Tamara Bittolo

Antonella Zucchetto

...

2022/6/1

Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft

Scientific reports

Lorena Landuzzi

Arianna Palladini

Claudio Ceccarelli

Sofia Asioli

Giordano Nicoletti

...

2021/1/15

IFN-γ and CD38 in Hyperprogressive Cancer Development

Stefania Angelicola

Francesca Ruzzi

Lorena Landuzzi

Laura Scalambra

Francesco Gelsomino

...

2021/1/15

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression

Oncogenesis

Veronica Giusti

Francesca Ruzzi

Lorena Landuzzi

Marianna L Ianzano

Roberta Laranga

...

2021/11/13

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy

Carla De Giovanni

Lorena Landuzzi

Arianna Palladini

Giordano Nicoletti

Patrizia Nanni

...

2021/7/16

The effect of Nannochloropsis oceanica feed inclusion on rabbit muscle proteome

Journal of proteomics

DM Ribeiro

J Bandarrinha

P Nanni

SP Alves

CF Martins

...

2020/6/30

See List of Professors in Patrizia Nanni University(Università degli Studi di Bologna)